Evidence suggests shedding is secondary to weight loss and nutritional shifts rather than direct follicular toxicity
Novo Nordisk holds semaglutide composition-of-matter and formulation patents expiring between 2031 and 2038 across different jurisdictions, with FlexTouch autoinjector device patents extending GLP-1 competitive protection in the U.S
Hydration matters enormously in the post-injection window
GLP-1 Weight Loss and Hair Loss: Why It Happens and What You Can Do About It If youve recently started taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication and have noticed increased shedding, youre not alone
What To Do If Wegovy Isnt Covered BCBS Appeal Process Have your provider submit an appeal or exception request to Blue Cross Blue Shield (BCBS)
Produced significant dose-dependent reductions in total body fat